Stock SVA SINOVAC BIOTECH LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sinovac Biotech Ltd.

Equities

SVA

AGP8696W1045

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2019-02-22 pm EST 		5-day change 1st Jan Change
6.47 USD -0.31% Intraday chart for Sinovac Biotech Ltd. -.--% -.--%
Jan. 18 Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital cancelled the acquisition of 10.04% stake in Sinovac Biotech Ltd. CI
2023 Scientists see risk of lost opportunity for long COVID research in China RE

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 449.3 479.4 640 639.9 642.4 642.4
Enterprise Value (EV) 1 375 316.3 457.3 -400 -12,628 -10,596
P/E ratio 17.5 x 20.6 x 15.8 x 6.66 x 0.09 x 6.49 x
Yield - - - - - -
Capitalization / Revenue 2.58 x 2.09 x 2.6 x 1.25 x 0.03 x 0.43 x
EV / Revenue 2.15 x 1.38 x 1.86 x -0.78 x -0.65 x -7.1 x
EV / EBITDA 7.48 x 6.29 x 6.23 x -1.82 x -0.72 x 34.5 x
EV / FCF 8.98 x -56.5 x 23.4 x -1.16 x -1.15 x 9.08 x
FCF Yield 11.1% -1.77% 4.27% -86.5% -87% 11%
Price to Book 2.99 x 1.95 x 2.18 x 0.86 x 0.07 x 0.07 x
Nbr of stocks (in thousands) 57,019 69,082 98,918 98,903 99,295 99,295
Reference price 2 7.880 6.940 6.470 6.470 6.470 6.470
Announcement Date 5/11/18 4/29/19 4/30/20 4/22/21 4/29/22 5/1/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 174.3 229.6 246.1 510.6 19,375 1,493
EBITDA 1 50.1 50.28 73.44 219.5 17,639 -307
EBIT 1 45.46 45.39 68.86 215.8 17,554 -460.9
Operating Margin 26.07% 19.77% 27.98% 42.26% 90.6% -30.87%
Earnings before Tax (EBT) 1 45.04 46.58 70.82 216.6 17,563 25.24
Net income 1 25.81 21.78 44.93 110.4 8,467 113.9
Net margin 14.8% 9.48% 18.26% 21.61% 43.7% 7.63%
EPS 2 0.4500 0.3365 0.4096 0.9710 74.27 0.9973
Free Cash Flow 1 41.74 -5.602 19.54 346 10,989 -1,166
FCF margin 23.94% -2.44% 7.94% 67.76% 56.72% -78.13%
FCF Conversion (EBITDA) 83.32% - 26.61% 157.64% 62.3% -
FCF Conversion (Net income) 161.73% - 43.49% 313.51% 129.78% -
Dividend per Share - - - - - -
Announcement Date 5/11/18 4/29/19 4/30/20 4/22/21 4/29/22 5/1/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 74.3 163 183 1,040 13,270 11,238
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 41.7 -5.6 19.5 346 10,989 -1,166
ROE (net income / shareholders' equity) 23.9% 15.4% 20.2% 25.2% 193% 0.66%
ROA (Net income/ Total Assets) 11.1% 8.48% 10.5% 11.5% 118% -1.87%
Assets 1 231.9 256.8 429.1 963 7,197 -6,101
Book Value Per Share 2 2.640 3.560 2.970 7.520 93.70 89.70
Cash Flow per Share 2 2.000 2.220 1.540 10.50 117.0 43.00
Capex 1 11.9 5.61 10.6 127 720 394
Capex / Sales 6.83% 2.44% 4.32% 24.97% 3.72% 26.38%
Announcement Date 5/11/18 4/29/19 4/30/20 4/22/21 4/29/22 5/1/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
SINOVAC BIOTECH LTD. Stock Sinovac Biotech Ltd.
-.--% 642M
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. SVA Stock
  4. Financials Sinovac Biotech Ltd.